Project Grant R01EB037010
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $151,040 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 12, 2026, with an ultimate completion date of September 14, 2028. The award supports research aimed at developing small molecule inhibitors of the E3 ligase NEDD4, an enzyme implicated in neurodegenerative disease, cardiovascular disease,...
- Summary of Federal Project Grant Award Brigham & Women's Hospital Inc. received a $1.554 million Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a trackerless surgical navigation system for minimally invasive liver surgery. The award, dated August 1, 2025, with performance extending through July 31, 2029, funds the...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Project Grant Award Summary Boston University received a $641.3K Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for the period May 1, 2026 through April 30, 2029. The award supports development of next-generation chemoproteomic probes for targeted profiling of oncogenic kinase activity in circulating tumor cells (CTCs). The...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Boston Children's Hospital a $996,466 Project Grant effective August 1, 2025, through May 31, 2029, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). This award supports the development of motion- and distortion-robust quantitative magnetic resonance imaging (QMRI) technology designed to enable advanced in-vivo analysis of...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $784,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2030. The grant funds a research initiative titled "Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFPEF in Characterizing Cardiometabolic Disease Phenotypes." The research employs...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Massachusetts General Hospital $656,750 through the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) on August 1, 2025, for a three-year project period concluding July 31, 2028. The award funds research to develop and optimize Electrical Impedance Tomography (EIT) as a bedside imaging tool for assessing lung perfusion in acute...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received a $893,459 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 9, 2026, with a completion date of March 31, 2031. This R01 resubmission award funds lipidomic discovery research focused on identifying physiological lipid antigens for human T cells and developing therapeutic blockers for CD1...
- Federal Project Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the Trustees of Boston University a Project Grant of $613,124 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for the period August 15, 2025, through July 31, 2028. The project delivers the development and demonstration of Quantitative Phase Imaging Meta-Sensors (PIMSs)—advanced optical imaging sensors that...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Massachusetts General Hospital a $133,077 Project Grant effective May 1, 2026 through April 30, 2028 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant supports development of a novel deep learning methodology for multi-modal biomedical data fusion that integrates three distinct data sources—clinical notes,...
Brigham and Women's Hospital Inc. received a $749,901 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for the period of May 1, 2026 through April 30, 2030. The award supports the development of an Interventional Drug Response Assay (IDRA) device designed to enable Phase-0 microdosing—a novel approach to drug development and personalized medicine that delivers minimal drug doses directly into target tissues for rapid evaluation of drug effects without systemic toxicity. The research addresses a critical clinical gap by developing a nonsurgical, percutaneously accessible interventional device that can deliver multiple drug microdoses and subsequently obtain biopsy specimens for multi-omic spatial analysis, thereby enabling broad clinical application in anatomically challenging locations where surgical resection is not feasible or safe. The IDRA technology represents a significant advancement over existing implantable microdevice platforms by eliminating the requirement for surgical tissue removal and analysis. This development aims to accelerate drug development timelines, reduce clinical trial failures, and enhance personalized treatment selection by providing direct measurements of how individual patients respond to candidate drugs in their own diseased tissues. The work conducted at the Boston, Massachusetts facility leverages Brigham and Women's Hospital's extensive research infrastructure and clinical expertise in advanced biomedical imaging and therapeutic device development, positioning the institution to translate fundamental discoveries into clinical applications that address unmet needs in neoadjuvant and metastatic cancer treatment.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $749.9k | 4/28/26 |